George Abercrombie

Insider profile

Currently holds positions in Brickell Biotech Inc and BioCryst Pharmaceuticals, Inc.

Performance

Overall performance
2.9
Performance over holding periods
2.9
30 days 90 days 120 days
Average return 4% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Brickell Biotech Inc Aug. 31, 2019 -
Independent Director BioCryst Pharmaceuticals, Inc. May 24, 2017 -
Senior Vice President, Chief Commercial Officer Innoviva Inc April 20, 2016 - Sept. 26, 2018
Non-Executive Independent Chairman of the Board BioCryst Pharmaceuticals, Inc. May 1, 2013 - May 24, 2017
Senior Vice President - Corporate Partnerships, Commercial Innoviva Inc June 12, 2014 - April 20, 2016
Independent Director Ocera Therapeutics Inc Sept. 19, 2011 - July 15, 2013
Independent Director BioCryst Pharmaceuticals, Inc. Oct. 10, 2011 - May 1, 2013
George Abercrombie's trades of BioCryst Pharmaceuticals, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2022-04-20 2022-04-18
PlS Planned sale
61,300 +20.1%
394.58
US$1,757,929 		61,300 +20.1% 394.58 US$1,757,929
2022-02-16 2022-02-15
PlS Planned sale
4,077 +50.0%
417.61
US$2,309,521 		4,077 +50.0% 417.61 US$2,309,521
2021-11-17 2021-11-15
PlS Planned sale
62,532 -16.5%
46.84
US$3,626,048 		62,532 -16.5% 46.84 US$3,626,048
2021-09-17 2021-09-15
PlS Planned sale
5,000 -100.0%
15.06
US$75,300 		5,000 -100.0% 15.06 US$75,300
2021-09-14 2021-09-10
S Sale
74,000 -100.0%
15.09
US$1,116,660 		74,000 -100.0% 15.09 US$1,116,660
2021-05-26 2021-05-24
PlS Planned sale
6,667 -69.0%
13.90
US$92,671 		6,667 -69.0% 13.90 US$92,671